Skip to main content

Table 3 Frequency of rituximab response according to myositis type, clinical involvement, autoantibody profile and treatment

From: Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies

  Responders (N = 29) Non-responders (N = 9) P
Age at disease diagnosis (years) 39.6 ± 12.2 28.3 ± 9.0 0.008
Age at Rituximab application (years) 44.7 ± 11.0 35.8 ± 8.1 0.017
Female gender 24 (82.7) 8 (88.9) 1.000
White ethnicity 19 (65.5) 7 (77.8) 0.689
Disease duration (years) 3.0 (1.5–5.5) 3.0 (2.0–10.0) 0.919
Duration: diagnosis - symptoms (months) 5.0 (3.0–8.0) 4.0 (2.5–12.0) 0.589
Myositis
 Dermatomyositis 14 (48.3) 1 (11.2) 0.061
 Polymyositis 6 (20.7) 4 (44.4) 0.205
 Antisynthetase syndrome 9 (31.0) 4 (44.4) 0.389
Clinical and laboratory features
 Dysphagia 18 (62.1) 9 (100.0) 0.038
 Articular 11 (37.9) 5 (55.6) 0.450
 Pulmonary 11 (37.9) 3 (33.3) 1.000
 Creatine phosphokinase (U/L) 5798 (2796–13,630) 9000 (4484–12,472) 0.457
 Aldolase (U/L) 36.1(18.7–42.3) 28.2 (20.6–40.6) 0.664
Autoantibodies
 Anti-Ro-52 11 (37.9) 5 (55.6) 0.450
 Anti-Jo-1 9 (31.0) 4 (44.4) 0.689
 Anti-Mi-2 4 (13.8) 0
 Anti-OJ 0 0
 Anti-EJ 0 0
 Anti-PL-7 0 0
 Anti-PL-12 0 0
 Antinuclear factor 23 (73.9) 8 (88.9) 1.000
Pre-RTX infusion protocol
 Methylprednisolone + intravenous human immunoglobulin pulse therapy 16 (55.2) 7 (77.8) 0.273
  1. Results expressed as mean ± standard deviation, median (25th - 75th) or percentage (%)
  2. RTX Rituximab